JP2002206000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002206000A5 JP2002206000A5 JP2001352728A JP2001352728A JP2002206000A5 JP 2002206000 A5 JP2002206000 A5 JP 2002206000A5 JP 2001352728 A JP2001352728 A JP 2001352728A JP 2001352728 A JP2001352728 A JP 2001352728A JP 2002206000 A5 JP2002206000 A5 JP 2002206000A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- fusion protein
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016267 Leptin Human genes 0.000 claims description 4
- 108010092277 Leptin Proteins 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 102000049953 human LEP Human genes 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 description 3
- 229920001308 poly(aminoacid) Polymers 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56173295A | 1995-11-22 | 1995-11-22 | |
| US08/561,732 | 1995-11-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51974597A Division JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002206000A JP2002206000A (ja) | 2002-07-23 |
| JP2002206000A5 true JP2002206000A5 (enExample) | 2007-04-05 |
| JP4227325B2 JP4227325B2 (ja) | 2009-02-18 |
Family
ID=24243198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51974597A Expired - Fee Related JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
| JP2001352728A Expired - Fee Related JP4227325B2 (ja) | 1995-11-22 | 2001-11-19 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51974597A Expired - Fee Related JP4173914B2 (ja) | 1995-11-22 | 1996-11-04 | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (3) | EP0866720B1 (enExample) |
| JP (2) | JP4173914B2 (enExample) |
| AT (2) | ATE455554T1 (enExample) |
| AU (3) | AU7607496A (enExample) |
| CA (2) | CA2236163A1 (enExample) |
| DE (2) | DE69638119D1 (enExample) |
| DK (1) | DK0866720T3 (enExample) |
| ES (2) | ES2339846T3 (enExample) |
| IL (2) | IL124442A0 (enExample) |
| MX (1) | MX9803992A (enExample) |
| NZ (3) | NZ512083A (enExample) |
| PT (1) | PT866720E (enExample) |
| SI (1) | SI0866720T1 (enExample) |
| WO (1) | WO1997018833A1 (enExample) |
| ZA (1) | ZA969605B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| DK0866720T3 (da) * | 1995-11-22 | 2004-06-14 | Amgen Inc | OB-protein til forögelse af mager kropsmasse |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| AU2246097A (en) * | 1996-01-25 | 1997-08-20 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
| WO1997039767A1 (en) * | 1996-04-19 | 1997-10-30 | Zymogenetics, Inc. | Methods for inducing bone formation |
| CA2274799A1 (en) * | 1996-12-20 | 1998-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| ATE351910T1 (de) * | 1996-12-20 | 2007-02-15 | Amgen Inc | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| EP0950417A3 (en) | 1998-02-23 | 2000-02-23 | Pfizer Products Inc. | Treatment of skeletal disorders |
| AU3863699A (en) * | 1998-04-20 | 1999-11-08 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis with leptin |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| EP1128840A1 (en) * | 1998-10-27 | 2001-09-05 | Eli Lilly And Company | Prevention of muscle mass loss with leptin receptor ligands |
| ES2257287T3 (es) * | 1999-02-12 | 2006-08-01 | Amgen Inc. | Composiciones de leptina glicosiladas y metodos relacionados. |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| AU2002359288B2 (en) | 2001-10-22 | 2008-07-31 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| WO2006005058A2 (en) * | 2004-06-30 | 2006-01-12 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| WO2008048691A2 (en) * | 2006-10-18 | 2008-04-24 | Amylin Pharmaceuticals, Inc. | Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| HUE040496T2 (hu) | 2012-09-27 | 2019-03-28 | Childrens Medical Ct Corp | Vegyületek elhízás kezelésére és alkalmazási eljárásaik |
| SI3074033T1 (sl) | 2013-11-26 | 2019-03-29 | The Children's Medical Center Corporation | Spojine za zdravljenje debelosti in postopki njihove uporabe |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| PL3509624T3 (pl) | 2016-09-12 | 2024-03-25 | Amryt Pharmaceuticals Inc. | Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228925B (it) * | 1987-08-07 | 1991-07-10 | Eniricerche Spa | Procedimento per la preparazione dell'ormone della crescita umano |
| DK173142B1 (da) * | 1988-08-24 | 2000-02-07 | Natinco Nv | Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| JPH09503973A (ja) * | 1993-08-13 | 1997-04-22 | プッツマイスター・ヴェルク マシーネンファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大型対象物の表面を処理する方法および装置 |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| DK0866720T3 (da) * | 1995-11-22 | 2004-06-14 | Amgen Inc | OB-protein til forögelse af mager kropsmasse |
| CA2238307A1 (en) * | 1995-12-27 | 1997-07-10 | Genentech, Inc. | Ob protein derivatives having prolonged half-life |
| ATE351910T1 (de) * | 1996-12-20 | 2007-02-15 | Amgen Inc | Ob-fusionsprotein enthaltende zusammensetzungen und verfahren |
| AU7132798A (en) * | 1997-04-17 | 1998-11-11 | Amgen, Inc. | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods |
-
1996
- 1996-11-04 DK DK96938773T patent/DK0866720T3/da active
- 1996-11-04 AT AT02011474T patent/ATE455554T1/de not_active IP Right Cessation
- 1996-11-04 WO PCT/US1996/017718 patent/WO1997018833A1/en not_active Ceased
- 1996-11-04 IL IL12444296A patent/IL124442A0/xx not_active IP Right Cessation
- 1996-11-04 CA CA002236163A patent/CA2236163A1/en active Pending
- 1996-11-04 ES ES02011474T patent/ES2339846T3/es not_active Expired - Lifetime
- 1996-11-04 EP EP96938773A patent/EP0866720B1/en not_active Expired - Lifetime
- 1996-11-04 NZ NZ512083A patent/NZ512083A/xx not_active IP Right Cessation
- 1996-11-04 NZ NZ511617A patent/NZ511617A/en not_active IP Right Cessation
- 1996-11-04 JP JP51974597A patent/JP4173914B2/ja not_active Expired - Fee Related
- 1996-11-04 CA CA002358862A patent/CA2358862A1/en not_active Abandoned
- 1996-11-04 SI SI9630675T patent/SI0866720T1/xx unknown
- 1996-11-04 ES ES96938773T patent/ES2217327T3/es not_active Expired - Lifetime
- 1996-11-04 EP EP98119160A patent/EP0956862A1/en not_active Withdrawn
- 1996-11-04 DE DE69638119T patent/DE69638119D1/de not_active Expired - Lifetime
- 1996-11-04 AT AT96938773T patent/ATE259243T1/de active
- 1996-11-04 DE DE69631544T patent/DE69631544T2/de not_active Expired - Lifetime
- 1996-11-04 PT PT96938773T patent/PT866720E/pt unknown
- 1996-11-04 EP EP02011474A patent/EP1285664B1/en not_active Expired - Lifetime
- 1996-11-04 AU AU76074/96A patent/AU7607496A/en not_active Abandoned
- 1996-11-04 NZ NZ527007A patent/NZ527007A/en not_active IP Right Cessation
- 1996-11-15 ZA ZA969605A patent/ZA969605B/xx unknown
-
1998
- 1998-05-20 MX MX9803992A patent/MX9803992A/es not_active IP Right Cessation
-
1999
- 1999-01-05 IL IL127926A patent/IL127926A/en not_active IP Right Cessation
-
2000
- 2000-06-23 AU AU42653/00A patent/AU763769B2/en not_active Ceased
- 2000-06-23 AU AU42652/00A patent/AU763755B2/en not_active Ceased
-
2001
- 2001-11-19 JP JP2001352728A patent/JP4227325B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002206000A5 (enExample) | ||
| Guichard et al. | Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. | |
| JP2018171063A5 (enExample) | ||
| PL363071A1 (pl) | Sposoby i kompozycje dla zmniejszenia replikacji HIV-1 | |
| CA2251464A1 (en) | Non-dendritic backbone peptide carrier | |
| WO2006076410A3 (en) | Li-key/antigenic epitope hybrid peptide vaccines | |
| WO1991008220A1 (en) | A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines | |
| JP2005502332A5 (enExample) | ||
| ATE478089T1 (de) | Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen | |
| US7122193B1 (en) | Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis | |
| US6245904B1 (en) | Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific T-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide | |
| CA2522329A1 (en) | Inhibitors of coronavirus | |
| JP2004532896A5 (enExample) | ||
| CN118891059A (zh) | 嵌合多肽 | |
| Löwenadler et al. | Enhanced immunogenicity of recombinant peptide fusions containing multiple copies of a heterologous T helper epitope | |
| RU2001127439A (ru) | Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом | |
| Park et al. | Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope | |
| TW200838558A (en) | New immunomodulating oligopeptides | |
| Astori et al. | Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic | |
| DK1719520T3 (en) | ANTIGENE EPITOPES OF REGULATION PROTEIN OF VIRULENS FACTOR IN STAPHYLOCOCCUS AUREUS AND MIMOTOPES THEREOF AND USE | |
| Leist et al. | Antibodies to synthetic polypeptides corresponding to hydrophilic regions of human interferon gamma | |
| Jakab et al. | Synthesis and antibody recognition of cyclic epitope peptides, together with their dimer and conjugated derivatives based on residues 9− 22 of herpes simplex virus type 1 glycoprotein D | |
| AU757334B2 (en) | Specific binding proteins for treating canine allergy | |
| JP2004509846A (ja) | 肝炎ｃ型ウイルスコンジュゲート | |
| US6764689B1 (en) | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications |